Isosceles Pharmaceuticals is a preclinical stage biotech company that is working on perioperative acute pain product candidates.
Isosceles Pharmaceuticals has raised $5.0M in total funding. The most recent round was Equity Crowdfunding. The last funding was announced in October 2022.
Isosceles Pharmaceuticals's investors include Equifund.
Isosceles Pharmaceuticals is headquartered in Wilmington, United States.
Isosceles Pharmaceuticals is a preclinical stage biotech company that is working on perioperative acute pain product candidates.
Isosceles Pharmaceuticals is at the Equity Crowdfunding stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Isosceles Pharmaceuticals — Funding & Investors." VCBacked, October 3, 2022, https://www.vcbacked.co/company/isosceles-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2022). Isosceles Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/isosceles-pharmaceuticals
{{cite web |title=Isosceles Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/isosceles-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated